Vanguard Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX

Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,455,790 shares of the medical instruments supplier’s stock after acquiring an additional 147,041 shares during the period. Vanguard Group Inc. owned approximately 11.32% of Becton, Dickinson and Company worth $6,074,750,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. RiverGlades Family Offices LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $344,000. Oppenheimer Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after purchasing an additional 34,437 shares during the period. Transcend Capital Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 88.2% during the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares during the period. Finally, Belpointe Asset Management LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $650,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,463 shares of company stock worth $501,530 over the last ninety days. 0.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BDX shares. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective on the stock. Zacks Research downgraded Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a research note on Tuesday, February 10th. Wells Fargo & Company cut their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Finally, Bank of America upped their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Trading Down 1.0%

Becton, Dickinson and Company stock opened at $175.95 on Tuesday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $185.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a market capitalization of $50.10 billion, a PE ratio of 28.70, a price-to-earnings-growth ratio of 2.30 and a beta of 0.25. The firm has a 50 day simple moving average of $198.55 and a 200-day simple moving average of $192.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the company posted $3.43 EPS. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.